

**From:** Prof. Philippe Gillery – IFCC SD Chair

**Date:** November 30<sup>th</sup>, 2022

**Ref:** 8.2.24 Call for Nominations for Membership of Committee on Reference Intervals and Decision Limits (C-RIDL)

## Scientific Division (SD)

### Chair

**Prof. Philippe GILLERY**

Service de Biochimie - Pharmacologie  
- Toxicologie  
Pôle de Biologie Médicale et  
Pathologie  
CHU de Reims  
Pôle de Biologie Territoriale  
51092 Reims Cedex - FRANCE  
E-mail: [pgillery@chu-reims.fr](mailto:pgillery@chu-reims.fr)

### Vice-Chair

**Prof. Christa M. COBBAERT**

Clinical Chemist  
Head of the Department of Clinical Chemistry  
Leiden University Medical Center  
2300 RC Leiden – THE NETHERLANDS  
E-mail: [C.M.Cobbaert@lumc.nl](mailto:C.M.Cobbaert@lumc.nl)

### Secretary

**Prof. Garry JOHN**

Department of Clinical Biochemistry and  
Immunology  
Norfolk and Norwich University Hospital  
Norwich NR4 7UY - UK  
E-mail: [g.john@nhs.net](mailto:g.john@nhs.net)

### Members

**Dr. Barnali DAS**

Lead Consultant, Biochemistry & Immunology  
Kokilaben Dhirubhai Ambani Hospital &  
Medical Research Institute,  
Mumbai-400053 - INDIA  
E-mail: [drbarnalid@gmail.com](mailto:drbarnalid@gmail.com)

**Dr. Konstantinos MAKRIS**

Clinical Biochemist  
Clinical Biochemistry Department  
KAT General Hospital  
Kifissia, Athens - GREECE  
E-mail: [kostas.makris.km@gmail.com](mailto:kostas.makris.km@gmail.com)

**Prof. Mario PLEBANI**

Full Professor of Clinical Biochemistry and  
Clinical Molecular Biology  
Chief Department of Laboratory Medicine  
University Hospital – Padova  
Dean of the Medical School  
University of Padova – ITALY  
E-mail: [mario.plebani@unipd.it](mailto:mario.plebani@unipd.it)

### Corporate Representative

**Dr. Michael ROTTMANN**

Roche Diagnostics GmbH  
Director Assay Development  
Indication: Thyroid, Sepsis, RA, Growth Centralised  
and Point of Care solutions  
82377 Penzberg - GERMANY  
e-mail: [michael.rottmann@roche.com](mailto:michael.rottmann@roche.com)

### Bureau International des Poids et Mesures

#### BIPM Observer

**Dr. Ralf D. JOSEPHS**

Principal Chemist  
Pavillon de Breteuil  
92312 Sèvres Cedex - FRANCE  
E-mail: [ralf.josephs@bipm.org](mailto:ralf.josephs@bipm.org)

### European Commission –

#### JRC Observer

**Dr. Liesbet DEPREZ**

Project Officer  
Directorate General Joint Research Centre  
Reference Materials Unit  
2440 Geel – BELGIUM  
E-mail: [Liesbet.deprez@ec.europa.eu](mailto:Liesbet.deprez@ec.europa.eu)

### ICHCLR Observer

**Prof. Ian S. YOUNG**

Professor of Medicine  
Queen's University Belfast  
The Center for Public Health  
1st floor - ICS B block  
Royal Victoria Hospital  
BT12 6BJ - Belfast - UK  
E-mail: [I.Young@qub.ac.uk](mailto:I.Young@qub.ac.uk)

### JCTLM Consultant

**Dr. Greg MILLER**

Professor of Pathology  
Co-Director of Clinical Chemistry  
Director of Pathology Information Systems  
Virginia Commonwealth University Health System  
Richmond, VA 23298-0286 - USA  
Email: [greg.miller@vcuhealth.org](mailto:greg.miller@vcuhealth.org)

### NIBSC Consultant

**Dr. Chris BURNS PhD**

Head, Biotherapeutics Division  
National Institute for Biological Standards and  
Control - A Centre of the MHRA  
Hertfordshire, EN6 3QG, UK  
E-mail: [Chris.Burns@nibsc.org](mailto:Chris.Burns@nibsc.org)

### NIFDC Observer

**Dr. Yang Zhen**

Deputy Director General  
National Institutes for Food and Drug Controls  
(NIFDC) - P.R. CHINA  
E-mail: [yangzhen@nifdc.org.cn](mailto:yangzhen@nifdc.org.cn)

### NIST Consultant

**Dr. Karen W. PHINNEY**

Leader, Bioanalytical Science Group  
Biomolecular Measurement Division  
National Institute of Standards  
and Technology (NIST)  
Gaithersburg, MD 20899-8314 - USA  
E-mail: [karen.phinney@nist.gov](mailto:karen.phinney@nist.gov)

**To: IFCC Full Member Societies' National Representatives  
IFCC Affiliate Societies' Representatives  
IFCC Corporate Members' Representatives**

Dear Colleagues,

In 2005, the IFCC established a Committee on Reference Intervals and Decision Limits (C-RIDL). Since then, the Committee has provided IFCC with high level expertise in the specific area of metrological traceability and standardization. The Committee, under the Chairmanship of Dr. Thomas Streichert, wishes to appoint one new member to substitute one officer who has completed the term of office. The time in office will begin on January 1<sup>st</sup>, 2023.

The specific terms of reference of this Committee are:

- To review current concepts of establishing reference intervals and decision limits and to prepare state-of-the-art position statements regarding new avenues
- To make available reference intervals and decision limits that respect the requirements of international regulations such as the European IVD Regulation 2017/746 and the IVDR amendment, and relevant ISO standards, especially ISO 17511 on metrological traceability of test results.
- To determine a priority list of measurands (analytes) for which standardized (preferred choice) and / or harmonized (2<sup>nd</sup> choice) reference intervals and/or decision limits have to be developed, considering various factors, such as age, gender, ethnicity, and for which the greatest improvements in medical decision making are anticipated. Alignment with IFCC SD EC prioritized analytes for standardization or harmonization is key.
- To monitor and evaluate currently proposed reference intervals for selected measurands (analytes) in the light of the concept of metrological traceability and of the identification of maximum allowable uncertainty.
- To establish transferability protocols of reference intervals and decision limits, which take into consideration inter-routine laboratory method variations and achieve better applicability in clinical practice
- To ask proactively input from IFCC SD EC and/or to collaborate with other organizations and/or to undertake establishment of reference intervals or decision limits for measurands (analytes) identified as a priority.
- To work in close collaboration with other Cs and WGs of SD and other IFCC Divisions for the development, education and appropriate clinical utilization of reference intervals and decision limits

### Current Projects:

- Conduction of a new study to compare alternative approaches (conventional and big data) for the determination of reference intervals taking into account the concepts of metrological traceability in time and space;
- Collaboration with the TF-GRID to create a website providing standardized/harmonized reference intervals obtained from studies;
- Preparation of a publication on comparison of direct and indirect approaches for the estimation of reference intervals.

The selected candidate will have a demonstrable expertise in the area of epidemiology, biostatistics of population studies, and, above all, they should be able to provide a practical contribution by actively participating in multicenter reference intervals studies. Nomination of a young scientist is welcome.

Nominations should be directly sent to the IFCC Office ([paola.bramati@ifcc.org](mailto:paola.bramati@ifcc.org)) using the attached Application Form, **by January 6<sup>th</sup>, 2022.**

The application must include:


- 1) Name, Institution address, telephone number and e-mail address of the nominee.
- 2) A full description of his/her professional career particularly highlighting the issues which could be important for his/her selection.
- 3) National Society's letter of support.

Following approval, the candidate will be appointed for a three-year term on the C-RIDL starting January 2023. A second three-year term is allowed following satisfactory review at the end of the first term by the SD Executive Committee following consultation with the C-RIDL Chair.

Looking forward to receiving your nomination, I remain

Yours sincerely

Prof. Philippe Gillery, MD, PhD

A handwritten signature in black ink, appearing to be 'P. Gillery', written over a horizontal line.

Chair IFCC Scientific Division  
Yours sincerely